title: Early effects of sodium valproate monotherapy on serum paraoxonase/arylesterase activities.
abstract: OBJECTIVE
  Valproic acid (VPA) treatment and paraoxonase1/arylesterase (PON1/Aryl) activities are related to the production of free radicals. Our aim was to study the PON1/Aryl activities in children on VPA therapy.
  
  
  METHODS
  Thirty-two children with seizures and 30 healthy child volunteers took part. Ill children underwent the common laboratory tests, as well as total antioxidant status (TAS), total oxidant status (TOS), lipid profile, liver enzymes and PON1/Aryl activities pre- and post-60 days on VPA therapy (30 mg/kg/24 h), whereas the healthy children were tested just once.
  
  
  RESULTS
  None of the studied biochemical parameters differed between volunteers and children with seizures pretreatment. Liver enzymes, lipids and TOS levels (124+/-30 versus 580+/-40 micromol/L; p<0.001) were significantly elevated, whereas the activities of PON1/Aryl (146+/-43 versus 118+/-40 U/mL/min 120+/-42 versus 98+/-38 KU/mL/min; p<0.01) and TAS levels (436+/-42 versus 288+/-39 micromol/L; p<0.001) were decreased in children after treatment. Additionally, strong negative correlations were found between PON1/Aryl activities, liver enzymes, TOS (r = -0.69) and VPA levels (r = -0.57), whereas PON1/Aryl activities correlated positively with TAS, HDL and Apo A-I in all groups.
  
  
  CONCLUSIONS
  Serum PON1/Aryl activities were decreased after 60 days on VPA treatment, probably due to liver dysfunction and free radicals production by VPA, without excluding the possibility of a direct action of the drug on the enzymes.
authors.affiliation: Department of Medical Laboratories, Technological and Educational Institute of Athens, Athens, Greece.
authors.forename: George A
authors.initials: GA
authors.lastname: Karikas
authors.forename: Kleopatra H
authors.initials: KH
authors.lastname: Schulpis
authors.forename: Anastasia
authors.initials: A
authors.lastname: Bartzeliotou
authors.forename: Spyros
authors.initials: S
authors.lastname: Regoutas
authors.forename: Christina
authors.initials: C
authors.lastname: Thanopoulou
authors.forename: Vassiliki
authors.initials: V
authors.lastname: Papaevangelou
authors.forename: Aglaia
authors.initials: A
authors.lastname: Giannoulia-Karantana
authors.forename: Ioannis
authors.initials: I
authors.lastname: Papassotiriou
authors.forename: Athena
authors.initials: A
authors.lastname: Fytou-Pallikari
mesh_terms: D000975:Antioxidants / Q000378:metabolism; D043303:Aryldialkylphosphatase / Q000097:blood*; D002265:Carboxylic Ester Hydrolases / Q000097:blood*; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D016877:Oxidants / Q000097:blood; D012640:Seizures / Q000097:blood / Q000188:drug therapy / Q000201:enzymology; D014635:Valproic Acid / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000975:Antioxidants; D008055:Lipids; D016877:Oxidants; D014635:Valproic Acid; D002265:Carboxylic Ester Hydrolases; C019734:arylesterase; D043303:Aryldialkylphosphatase